Ian Ingram from MedPage Today - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting		FDA Revokes EUAs of Four COVID-19 Monoclonal Antibodies - 7 days ago Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia - 12 days ago GLP-1 Drugs Tied to Reduced Risk of Dangerous Blood Clots - 13 days ago Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL - 14 days ago Lidocaine Fails to Speed Up Gut Function Recovery After Colonic Surgery - 21 days ago FDA Approves New Option for Rosacea - about 2 months ago Lebrikizumab Wins FDA Approval for Eczema - 3 months ago ERS Roundup: Air Filtration Succeeds in Reducing Infections - 3 months ago Inhaled Antibiotic for Bronchiectasis Shows Benefit ... and Then It Doesn't - 3 months ago Cheap Antidepressant Flops for Severe Breathlessness in Trial - 3 months ago FDA Expands Durvalumab Label to Operable Lung Cancer - 4 months ago FDA OKs First Point-of-Care Test for Detecting Hep C in At-Risk Adults - 6 months ago FDA Approves Pneumococcal Vax Designed Specifically for Adults - 6 months ago Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 6 months ago Rare Pregnancy Problem Linked to Thiopurines, FDA Says - 8 months ago FDA Approves Earlier Use of CAR-T Products for Myeloma - 9 months ago Are Trump Voters Predisposed to COVID Vax Side Effects?! - 9 months ago New Monoclonal Authorized to Prevent COVID in Immunocompromised People - 9 months ago FDA Approves New Frontline Regimen for Aggressive ALL - 9 months ago FDA Approves First CAR-T for Chronic Lymphocytic Leukemia - 9 months ago Latest COVID Shots Protect Against Serious Outcomes - 10 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 10 months ago FDA Approves First Drug for Severe Frostbite - 10 months ago FDA Approves First Oral Option for Eosinophilic Esophagitis - 10 months ago Bronchoscopes Recalled Over Burns, Fires in Patients' Airways - about 1 year ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - about 1 year ago FDA OKs Maintenance Option for High-Risk Neuroblastoma - about 1 year ago Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial - about 1 year ago Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder - about 1 year ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - about 1 year ago MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia - about 1 year ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - about 1 year ago Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials - about 1 year ago Completely Oral Regimen Effective, Feasible in APL - about 1 year ago Non-Covalent BTK Inhibitor Approved for CLL - about 1 year ago Two Approaches for Infected Necrotizing Pancreatitis Go Head-to-Head - about 1 year ago Higher-Dose Fluvoxamine Fails for COVID Outpatients - about 1 year ago First At-Home Test for Chlamydia and Gonorrhea Authorized by FDA - about 1 year ago Lymphoma Drug Copanlisib to Be Pulled From U.S. Market - about 1 year ago First Chikungunya Vaccine Lands Conditional FDA Approval - about 1 year ago New Oral Drug Approved for Metastatic Colorectal Cancer - about 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - about 1 year ago Randomized Trial Backs HIF-2a Inhibition in Advanced RCC - about 1 year ago Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years - about 1 year ago